Explaining why myasthenia patients relapse after treatment

11-Sep-2017 - USA

A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab, commonly used to treat the incurable autoimmune disease marked by muscle weakness and fatigue.

In patients with MG, B cells — a subset of white cells that produce antibodies — are abnormal and attack the neuromuscular junction in muscle tissue creating weakness and fatigue.

“While therapy with rituximab eliminates B cells, they remain abnormal after regenerating and contribute to relapse,” said Dr. Kevin C. O’Connor, associate professor of neurology and co-senior author of the report.

“Disease relapse following successful rituximab treatment could be predicted, allowing physicians to tailor therapy on an individual basis,” said Dr. Richard Nowak, the co-senior author of the report and director of the Yale Myasthenia Gravis Clinic.

Original publication

Other news from the department science

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous